The study of human embryonic stem cells (hESCs) and Induced Pluripotent Stem Cells (iPSC) and its differentiation into specific lineages provides an extraordinary opportunity to study the cellular / molecular mechanisms regulating pluripotency and differentiation. It also offers a potentially unlimited source of numerous cell types for drug screening and cell-based therapies. The Pluripotent Stem Cell Shared Resource Facility has been established to facilitate the transfer of this technology to the Mount Sinai community and other institutions. The objectives of this facility are:
To provide undifferentiated PSCs, mouse embryonic fibroblasts (MEFs) and/or hematopoietic, cardiac and endoderm progenitors. For more information please visit Getting Started
To train faculty, postdoctoral fellows and students in the maintenance and the differentiation of pluripotent stem cells. For more information please visit Services
To provide tested media / reagents necessary for the maintenance as well as the differentiation of pluripotent stem cells at discounted prices. For more information please visit Supply Center
To karyotype and bank hESC and iPSC stocks.
To generate gene targeted hESC lines (in collaboration with the mouse gene targeting facility).
To assist PIs with pilot hESC projects.
To assist PIs with the development of novel induced pluripotent stem (iPS) cell lines from human patients as well as their differentiation using footprint free methodologies including Sendai virus and mRNA/micro mRNA reprogramming.
Sameule Marro
Director of the Stem Cell Engineering Core
To provide undifferentiated PSCs, mouse embryonic fibroblasts (MEFs) and/or hematopoietic, cardiac and endoderm progenitors. For more information please visit Getting Started
To train faculty, postdoctoral fellows and students in the maintenance and the differentiation of pluripotent stem cells. For more information please visit Services
To provide tested media / reagents necessary for the maintenance as well as the differentiation of pluripotent stem cells at discounted prices. For more information please visit Supply Center
To karyotype and bank hESC and iPSC stocks.
To generate gene targeted hESC lines (in collaboration with the mouse gene targeting facility).
To assist PIs with pilot hESC projects.
To assist PIs with the development of novel induced pluripotent stem (iPS) cell lines from human patients as well as their differentiation using footprint free methodologies including Sendai virus and mRNA/micro mRNA reprogramming.
Sameule Marro
Director of the Stem Cell Engineering Core
